Avacta to present updated clinical data on AVA6000 at the European Society for Medical ...
Avacta Group to present updated Phase 1a trial data of AVA6000 at 2024 ESMO Congress in Barcelona, focusing on FAP-positive solid tumours. AVA6000 is a doxorubicin peptide drug conjugate targeting the tumour microenvironment.
Highlighted Terms
Related News
AVA6000 demonstrates safety and efficacy in FAP-positive solid tumors, with durable RECIST responses and reduced cardiac toxicity compared to conventional doxorubicin. The pre|CISION-enabled doxorubicin shows altered pharmacokinetics, suggesting improved tumor targeting and reduced systemic side effects.
Avacta Group to present updated Phase 1a trial data of AVA6000 at 2024 ESMO Congress in Barcelona, focusing on FAP-positive solid tumours. AVA6000 is a doxorubicin peptide drug conjugate targeting the tumour microenvironment.